We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Dicerna Pharmaceuticals Inc | NASDAQ:DRNA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 38.22 | 42.07 | 38.22 | 0 | 01:00:00 |
By Chris Wack
Dicerna Pharmaceuticals Inc. said that Eli Lilly and Co. has declared proof of principle for the first two targets in the companies' exclusive relationship in neurodegeneration and pain therapies, under the companies' global research and licensing collaboration.
This milestone triggers two single-digit multimillion-dollar milestone payments to Dicerna, which the company expects to receive in the fourth quarter.
"We are very pleased to announce Lilly's selection of two extrahepatic targets for advancement to preclinical development and initiation of associated IND-enabling studies under our discovery, development and licensing agreement," said Bob D. Brown, chief scientific officer at Dicerna. "These molecules represent the first targets under our collaboration with Lilly to address tissues outside the liver, highlighting the further expansion of our growing pipeline of RNAi therapeutics that address multiple tissues and cell types."
Dicerna and Lilly entered into a global licensing and research collaboration in 2018 focused on the discovery, development and commercialization of potential new therapies for cardiometabolic disease, neurodegenerative diseases and pain. Including the two targets highlighted on Friday, there are seven candidates in preclinical or clinical development.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
November 12, 2021 08:39 ET (13:39 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Dicerna Pharmaceuticals Chart |
1 Month Dicerna Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions